Changing Landscape of Therapeutic Development for Genetic ALS & All ALS
By: Suma Babu, MD, MPH, MBBS
Moving ctDNA Utilization Beyond Predictive Biomarkers: The Next Frontier
By: Christian Rolfo, MD, PhD, MBA, Dr.hc
Biosimilars Implementation in the US: A Five Year Review
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials
By: Paul Frankel - PhD
Integrating Biomarkers into Targeted Therapy and Immunotherapy Clinical Trials
By: Paul Frankel, PhD
The Challenges of Biosimilars in the Daily Oncology Practice?
By: Dina B. Dumercy McHenry, PharmD, MBA, BCOP
Biosimilars Implementation in the United States: Where Opportunities Remain
By: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE
Seven Years of Biosimilar Experience in the U.S., Where Untapped Value Remains
By: Jorge J. García, PharmD, MS, MHA, MBA, FACHE
